Analyst consensus rating
IN8bio Analyst Rating: none
INAB is rated none by 4 analysts with a $6.25 target. As of 2026-08-31.
Direct answer
IN8bio's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.25.
Forecast evidence checked August 31, 2026.
Get free IN8bio email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.04
- Average price target
- $6.25
- High price target
- $10.00
- Low price target
- $4.00
- Low target gap
- +286.5%
- Target upside
- +503.9%
- High target gap
- +866.2%
- Target range width
- 579.7%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- August 31, 2026
- Valid through
- September 7, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for IN8bio?
IN8bio has a verified none consensus. The same dataset has an average price target of $6.25.
How far are IN8bio's low and high targets from the recorded price?
The low target implies +286.5%, while the high target implies +866.2%.
How many analysts are included in IN8bio's consensus?
The verified consensus includes 4 analysts.
How is IN8bio's target upside or downside calculated?
The average target of $6.25 is divided by the recorded price of $1.04, then one is subtracted to produce +503.9%. This does not guarantee a future return.
When was IN8bio's analyst forecast verified?
The data was verified on 2026-08-31. The dataset is valid through 2026-09-07.